Publikationen (179) Publikationen von JUAN GÓMEZ-REINO CARNOTA

2022

  1. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review

    Seminars in Arthritis and Rheumatism, Vol. 52

2019

  1. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

  2. Specific Association of HLA–DRB1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 331-339

2018

  1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)

    Clinical Microbiology and Infection, Vol. 24, pp. S10-S20

  2. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

    The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224

  3. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

    PLoS ONE, Vol. 13, Núm. 5

2016

  1. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

  2. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

    Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345

  3. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis

    Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 238-245

  2. Documento práctico para el uso de abatacept subcutáneo

    Reumatologia Clinica, Vol. 10, Núm. 4, pp. 218-226

  3. Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus

    Arthritis Research and Therapy, Vol. 16, Núm. 3

  4. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  5. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2

2013

  1. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico

    Reumatologia Clinica, Vol. 9, Núm. 5, pp. 281-296

  2. El uso de abatacept en artritis reumatoide: Revisión de la evidencia y recomendaciones

    Reumatologia Clinica, Vol. 9, Núm. 1, pp. 5-17

2012

  1. Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: A case-control study

    Arthritis Research and Therapy, Vol. 14, Núm. 2

  2. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 11, pp. 1861-1864

  3. Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study

    PLoS ONE, Vol. 7, Núm. 9